PROVO, Utah--(BUSINESS WIRE)--GeNOsys (generated nitric oxide systems) Inc. (OTCBB: GNYS), a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems, announces the Company has successfully updated its hospital bedside Nitric Oxide (NO) generator and proprietary tablet. Once the Company’s flagship device receives its 510(K) approval, device sales to hospitals and laboratories are expected to reduce the patient cost as compared with existing cylinder delivered NO gas. The changes allow for improved NO production and regulation, which could result in increased standard of patent care. The reduced costs are expected to increase the use of NO substantially as well as provide for cost effective anti-viral and anti-bacterial treatments.
